Biotech Companies

706 companies | Drug discovery and development companies

#	COMPANY	THERAPEUTIC AREAS	STAGE
1.	1ST Biotherapeutics, Inc. Yongin, South Korea	Rare Diseases	Phase 1	VIEW
2.	3SBio Inc. Shenyang, China	Oncology Hematology Immunology	Phase 3	VIEW
3.	4 Animals AlsterScience GmbH Hamburg, Germany	Immunology Oncology Infectious Disease	Preclinical	VIEW
4.	4D Pharma plc Leeds, United Kingdom	Oncology Immunology Gastroenterology	Preclinical to Phase II (at time of administration)	VIEW
5.	AAVantgarde Bio Milan, Italy	Rare Diseases Ophthalmology	Phase 1/2	VIEW
6.	AC Immune SA Lausanne, Switzerland		Phase 2	VIEW
7.	ADARx Pharmaceuticals San Diego, USA	Neuroscience Immunology Oncology	Phase 3	VIEW
8.	ADMA Biologics, Inc. Ramsey, New Jersey, United States		Commercial + Preclinical	VIEW
9.	AGS Therapeutics Paris, France	Ophthalmology Immunology Infectious Disease+2	Preclinical	VIEW
10.	ALX Oncology South San Francisco, United States	Oncology	Phase 1 / Phase 2	VIEW
11.	ANSTO (Australian Nuclear Science and Technology Organisation) Sydney, Australia	Oncology Cardiovascular Neuroscience	Commercial	VIEW
12.	AbCellera Vancouver, Canada	Metabolic Immunology Oncology	Phase 2	VIEW
13.	Abbisko Therapeutics Shanghai, China	Oncology	Phase 3	VIEW
14.	Abcuro, Inc. Newton, Massachusetts, USA	Immunology Oncology Rare Diseases	Phase 2/3	VIEW
15.	Abdera Therapeutics South San Francisco, USA / Vancouver, Canada	Oncology	Phase 1	VIEW
16.	Abeona Therapeutics Inc. Cleveland, Ohio, USA	Rare Diseases Ophthalmology Dermatology	Commercial	VIEW
17.	Abivax Paris, France	Immunology Gastroenterology	Phase 3	VIEW
18.	Acadia Pharmaceuticals Inc. San Diego, USA	Neuroscience Rare Diseases	Commercial	VIEW
19.	Accent Therapeutics Lexington, Massachusetts, United States	Oncology	Phase 1/2	VIEW
20.	Acelot South San Francisco, California, USA	Metabolic Oncology	Preclinical	VIEW
21.	Acepodia Alameda, USA / Taipei, Taiwan	Oncology Immunology	Phase 1	VIEW
22.	Acerand Therapeutics Carmel, USA / Shanghai, China	Oncology Immunology	Phase 1/2	VIEW
23.	Actinogen Medical Sydney, Australia		Phase 2/3	VIEW
24.	AcuraStem Monrovia, California, USA		Preclinical	VIEW
25.	AdvantiGen Biosciences Madison, WI, United States	Oncology Immunology	Discovery	VIEW
26.	Aegros Macquarie Park, Australia	Infectious Disease Immunology	Clinical	VIEW
27.	Aerogen Pharma San Mateo, USA / Galway, Ireland	Respiratory	Phase 3	VIEW
28.	Affitech Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)	Oncology Immunology Infectious Disease	Clinical	VIEW
29.	AgeneBio Baltimore, MD, USA	Neuroscience	Phase 2	VIEW
30.	Agios Pharmaceuticals Cambridge, USA	Rare Diseases Hematology Metabolic	Commercial	VIEW
31.	Agomab Therapeutics Antwerp, Belgium	Gastroenterology Rare Diseases	Phase 2	VIEW
32.	AiCuris Anti-infective Cures AG Wuppertal, Germany	Infectious Disease	Phase 3	VIEW
33.	Aitia Somerville, Massachusetts, USA	Oncology Immunology	Discovery	VIEW
34.	Akebia Therapeutics Cambridge, USA	Rare Diseases	Commercial	VIEW
35.	Akeso, Inc. Guangdong, China	Oncology Immunology	Commercial	VIEW
36.	Akribes Biomedical Vienna, Austria	Dermatology	Preclinical	VIEW
37.	Alchemab Therapeutics Cambridge, United Kingdom	Oncology Immunology	Phase 1	VIEW
38.	Alderys Orsay, France		Discovery	VIEW
39.	AlgiPharma AS Sandvika, Norway	Respiratory Infectious Disease	Phase 2	VIEW
40.	Alkermes plc Dublin, Ireland	Neuroscience	Commercial	VIEW
41.	Alkeus Pharmaceuticals Cambridge, USA	Ophthalmology Rare Diseases	Phase 3	VIEW
42.	Allergy Therapeutics Worthing, United Kingdom		Phase 3 and Phase 1/2	VIEW
43.	Allotera Therapeutics St. Louis, USA	Oncology Hematology Immunology	Pivotal	VIEW
44.	Allotera Therapeutics (formerly Wugen, Inc.) St. Louis, USA	Oncology	Phase 2	VIEW
45.	Allygen Biosciences Shanghai, China	Oncology Immunology	Preclinical	VIEW
46.	AlphaGen Therapeutics Shanghai, China	Oncology	Preclinical	VIEW
47.	AltruBio, Inc. San Francisco, USA	Immunology	Phase 2	VIEW
48.	Alumis Inc. South San Francisco, USA	Immunology Dermatology Neuroscience+1	Phase 3	VIEW
49.	Alvotech Luxembourg, Luxembourg	Immunology Ophthalmology Oncology+1	Commercial	VIEW
50.	Amgen Thousand Oaks, California, United States	Oncology Immunology Metabolic+1	Discovery through Commercial	VIEW
51.	Amicus Therapeutics Princeton, New Jersey, USA	Rare Diseases Metabolic	Commercial	VIEW
52.	Amylyx Pharmaceuticals Cambridge, USA	Rare Diseases	Phase 3	VIEW
53.	Anavex Life Sciences Corp. New York, United States	Oncology	Phase 2\|Phase 3	VIEW
54.	Angal Biotechnologies Ltd. Suzhou, China	Oncology Infectious Disease	Preclinical	VIEW
55.	Anocca AB Södertälje, Sweden	Oncology Immunology Infectious Disease	Phase 1	VIEW
56.	Antares Therapeutics Boston, USA	Oncology	Preclinical	VIEW
57.	Anwita Biosciences, Inc. San Carlos, USA	Oncology	Phase 1	VIEW
58.	Anyea Therapeutics Co., Ltd. Shanghai, China	Neuroscience	Discovery	VIEW
59.	Apateya Bordeaux, France	Neuroscience	Preclinical	VIEW
60.	Apeiron Therapeutics (GT Apeiron LLC) Burlingame, USA / Shanghai, China	Oncology	Phase 1	VIEW
61.	Apellis Pharmaceuticals, Inc. Waltham, Massachusetts, USA	Ophthalmology Rare Diseases Immunology	Commercial	VIEW
62.	Apogee Therapeutics, Inc. Waltham, USA	Dermatology Respiratory	Phase 2	VIEW
63.	Appili Therapeutics Inc. Halifax, Canada	Infectious Disease	Commercial	VIEW
64.	Aprogen Seongnam-si, South Korea	Oncology Immunology	Commercial	VIEW
65.	Aptose Biosciences Inc. Toronto, Canada	Oncology Hematology	Phase 2	VIEW
66.	Aquinas Companies, LLC (Fannin Innovation Studio) Houston, Texas, USA	Oncology Infectious Disease Cardiovascular+2	Phase 2	VIEW
67.	Araceli Biosciences Tigard, Oregon, United States		Seed	VIEW
68.	Aramis Biotechnologies Quebec City, Canada	Infectious Disease	Phase 1/2	VIEW
69.	Arcus Biosciences Hayward, United States	Oncology Immunology	Phase 3	VIEW
70.	Ardelyx Waltham, Massachusetts, USA	Gastroenterology	Commercial	VIEW
71.	Argo Biopharma Shanghai, China	Cardiovascular Metabolic Hematology+2	Phase 2	VIEW
72.	Ark Biosciences Shanghai, China	Respiratory Infectious Disease Neuroscience	Commercial	VIEW
73.	Arrivo BioVentures Morrisville, USA	Neuroscience Gastroenterology	Phase 2	VIEW
74.	Arrowhead Pharmaceuticals Pasadena, California, United States	Metabolic	Commercial \| Phase 3 \| Phase 2 \| Phase 1	VIEW
75.	Artica Therapeutics Leiden, Netherlands	Immunology	Preclinical	VIEW
76.	Artificial Axon Labs Cambridge, Massachusetts, USA	Neuroscience	Discovery	VIEW
77.	Artios Pharma Cambridge, United Kingdom	Oncology	Phase 2	VIEW
78.	Artiva Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
79.	Arvinas, Inc. New Haven, Connecticut, United States	Oncology Neuroscience	Phase 1-3	VIEW
80.	AryoGen Pharmed Karaj, Iran	Oncology Immunology Hematology	Commercial	VIEW
81.	Ascentage Pharma Suzhou, China	Oncology	Commercial	VIEW
82.	Asclepii Cleveland, USA		Commercial	VIEW
83.	AskGene Camarillo, California, United States	Oncology Immunology Ophthalmology	Phase 3	VIEW
84.	Asklepios BioPharmaceutical Research Triangle Park, North Carolina, USA	Metabolic	Phase 1\|Phase 2\|Preclinical	VIEW
85.	Aspect Biosystems Vancouver, Canada	Metabolic	Preclinical	VIEW
86.	AtaiBeckley (formerly ATAI Life Sciences) Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025		Phase 2	VIEW
87.	Atara Biotherapeutics, Inc. Thousand Oaks, California, USA	Oncology Immunology	Clinical	VIEW
88.	Atea Pharmaceuticals Boston, Massachusetts, United States		Phase 3 (HCV), Phase 1 planned (HEV)	VIEW
89.	AudioCure Pharma GmbH Berlin, Germany		Phase 2	VIEW
90.	Aurefluidics Shanghai, China	Oncology Cell Therapy Gene Therapy	Commercial	VIEW
91.	Aurion Biotech Seattle, USA	Ophthalmology	Phase 3	VIEW
92.	AusperBio San Francisco, USA	Infectious Disease	Phase 2	VIEW
93.	Autobahn Therapeutics San Diego, USA	Neuroscience	Phase 2	VIEW
94.	Autolus Therapeutics London, United Kingdom	Oncology Immunology Rare Diseases	Commercial + Phase 1/2	VIEW
95.	Avenzo Therapeutics San Diego, USA	Oncology	Phase 2	VIEW
96.	Axalbion Lausanne, Switzerland	Respiratory Ophthalmology Neuroscience	Phase 2	VIEW
97.	BIKEN Foundation Suita, Japan	Infectious Disease	Commercial	VIEW
98.	BIOCAD Saint Petersburg, Russia	Oncology Immunology Infectious Disease	Commercial	VIEW
99.	BIOVIIIx Naples, Italy	Rare Diseases Hematology Oncology	Discovery	VIEW
100.	BPS Bioscience, Inc. San Diego, California, United States	Oncology Immunology Infectious Disease	Discovery	VIEW
101.	BRIM Biotechnology, Inc. Taipei, Taiwan	Ophthalmology Rare Diseases	Phase 3	VIEW
102.	Bavarian Nordic A/S Hellerup, Denmark	Infectious Disease Oncology Immunology	Commercial	VIEW
103.	BeBetter Med Inc. Guangzhou, China	Oncology	Commercial	VIEW
104.	Beeline Medicines Boston, USA	Immunology Dermatology	Phase 2	VIEW
105.	Beijing Sungen Biomedical Technology Co., Ltd. Beijing, China	Cardiovascular Oncology Infectious Disease	Phase 2	VIEW
106.	Belenos Biosciences New York, NY, USA	Immunology Respiratory Dermatology	Phase 1/2	VIEW
107.	Belief BioMed Shanghai, China	Rare Diseases Hematology Neuroscience+1	Commercial	VIEW
108.	BenevolentAI London, United Kingdom	Oncology Immunology Neuroscience+3	Phase 1\|Phase 2\|Preclinical	VIEW
109.	Benitec Biopharma Inc. Hayward, California, USA	Infectious Disease Oncology	Phase 1b/2a (BB-301), Preclinical (other programs)	VIEW
110.	Beren Therapeutics P.B.C. Thousand Oaks, USA	Rare Diseases	Phase 3	VIEW
111.	Berg Health Framingham, Massachusetts, USA	Oncology Neuroscience Rare Diseases	Phase 1/2	VIEW
112.	Bharat Serums and Vaccines Limited (BSV Group) Navi Mumbai, India		Commercial	VIEW
113.	Bicycle Therapeutics plc Cambridge, United Kingdom	Oncology	Phase 2	VIEW
114.	Bio Pharma Eco SL Spain		Discovery	VIEW
115.	Bio Usawa Inc. San Mateo, USA / Kigali, Rwanda	Oncology Infectious Disease Ophthalmology	Preclinical	VIEW
116.	BioCardia, Inc. Sunnyvale, California, USA	Cardiovascular Respiratory	Phase 3	VIEW
117.	BioChain Institute Inc. Newark, California, USA	Oncology Neuroscience Immunology+1	Commercial	VIEW
118.	BioInvent International AB Lund, Sweden	Oncology	Phase 2	VIEW
119.	BioLineRx Ltd. Modiin, Israel	Oncology Rare Diseases	Commercial	VIEW
120.	BioMarin Pharmaceutical Inc. San Rafael, USA	Hematology Metabolic Cardiovascular	Commercial	VIEW
121.	BioMed Valley Discoveries Kansas City, Missouri, USA	Oncology Immunology Rare Diseases+1	Clinical (Phase 1-2)	VIEW
122.	BioNTech Mainz, Germany	Oncology Immunology Infectious Disease	Phase 1-3	VIEW
123.	BioNTech SE Mainz, Germany	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
124.	BioOra Limited Wellington, New Zealand	Oncology	Phase 2	VIEW
125.	Biocase Brasil Itajaí, Brazil		Preclinical	VIEW
126.	Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Beijing, China	Oncology Immunology Metabolic+1	Phase 2	VIEW
127.	Biohaven Ltd. New Haven, USA	Neuroscience Immunology Oncology+1	Phase 3	VIEW
128.	Biological E. Limited Hyderabad, India	Infectious Disease Gastroenterology	Commercial	VIEW
129.	BiomeBank Adelaide, Australia	Infectious Disease Gastroenterology Metabolic	Clinical	VIEW
130.	Biomea Fusion San Carlos, USA	Metabolic Oncology	Phase 2	VIEW
131.	Biomed Industries, Inc. San Jose, USA	Metabolic	Phase 2/3	VIEW
132.	Biovet AD Peshtera, Bulgaria		Commercial	VIEW
133.	Bioxodes Gosselies, Belgium	Neuroscience Immunology	Phase 2	VIEW
134.	BirchBioMed Inc. Vancouver, Canada	Dermatology Rare Diseases	Phase 2/3	VIEW
135.	BlossomHill Therapeutics San Diego, USA	Oncology Immunology	Phase 1	VIEW
136.	BlueRock Therapeutics Cambridge, USA	Neuroscience Cardiovascular Ophthalmology+1	Phase 3	VIEW
137.	Blueprint Medicines Cambridge, USA	Oncology Hematology Immunology+1	Commercial	VIEW
138.	Boostimmune Seoul, South Korea	Oncology Immunology	Preclinical	VIEW
139.	Bota Biosciences Hangzhou, China (International HQ in Lafayette, CA, USA)		Commercial	VIEW
140.	BrainXell, Inc. Madison, WI, USA	Neuroscience Rare Diseases	Preclinical	VIEW
141.	BridgeBio Oncology Therapeutics, Inc. South San Francisco, USA	Oncology	Phase 1	VIEW
142.	Bright Peak Therapeutics Allschwil, Switzerland	Oncology	Phase 1/2a	VIEW
143.	Brise Pharmaceuticals Shanghai, China		Phase 2	VIEW
144.	Broad Institute of MIT and Harvard Cambridge, USA	Oncology Rare Diseases Cardiovascular+1	Discovery	VIEW
145.	BunyaVax Lelystad, Netherlands	Infectious Disease Oncology	Phase 1	VIEW
146.	Byondis Nijmegen, Netherlands	Oncology	Phase 1	VIEW
147.	CAMP4 Therapeutics Cambridge, USA	Rare Diseases	Phase 1	VIEW
148.	CDR-Life Schlieren, Zurich, Switzerland	Oncology Immunology Ophthalmology	Phase 1	VIEW
149.	CEA (Commissariat à l'énergie atomique et aux énergies alternatives) Paris and Gif-sur-Yvette, France	Infectious Disease Oncology	Discovery	VIEW
150.	CEPI Oslo, Norway	Infectious Disease	Commercial	VIEW
151.	CG Oncology, Inc. Irvine, USA	Oncology	Phase 3	VIEW
152.	CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland	Oncology Immunology Neuroscience+2	Phase 3	VIEW
153.	CPTx Planegg, Germany	Oncology Immunology Infectious Disease	Preclinical	VIEW
154.	CRUK Scotland Institute Glasgow, United Kingdom	Oncology	Discovery	VIEW
155.	CSL Limited Melbourne, Australia	Immunology Hematology Cardiovascular+3	Commercial	VIEW
156.	CSL Limited (CSL Behring is the largest division) Melbourne, Australia (corporate); King of Prussia, USA (CSL Behring)	Immunology Hematology Respiratory+1	Phase 1 through Commercial	VIEW
157.	CSL Seqirus Maidenhead, United Kingdom		Commercial	VIEW
158.	CURE5 Foundation New York, USA	Rare Diseases Neuroscience	Discovery	VIEW
159.	Caldera Therapeutics Cambridge, USA	Immunology Gastroenterology	Phase 1	VIEW
160.	Calico Life Sciences South San Francisco, United States	Oncology Neuroscience Immunology	Phase 2	VIEW
161.	Calidi Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
162.	Calliditas Therapeutics Stockholm, Sweden	Rare Diseases	Commercial	VIEW
163.	Calluna Pharma Oslo, Norway	Immunology	Phase 2	VIEW
164.	Camelx Riyadh, Saudi Arabia		Discovery	VIEW
165.	Camurus AB Lund, Sweden	Neuroscience Rare Diseases Metabolic+1	Commercial	VIEW
166.	CanariaBio Inc. Seoul, South Korea	Oncology	Phase 3	VIEW
167.	Canopy Immuno-Therapeutics Megadim, Israel		Preclinical	VIEW
168.	Cantargia AB Lund, Sweden	Oncology Immunology	Phase 1 - Phase 2	VIEW
169.	Captor Therapeutics Wroclaw, Poland	Oncology Immunology	Preclinical	VIEW
170.	Capulus Therapeutics LLC San Francisco, United States	Oncology	Preclinical	VIEW
171.	Cardurion Pharmaceuticals Burlington, United States	Cardiovascular	Phase 2	VIEW
172.	Carrick Therapeutics Dublin, Ireland	Oncology	Phase 2	VIEW
173.	Cell-Tx Seoul, South Korea	Neuroscience Oncology Ophthalmology	Preclinical	VIEW
174.	Cellectar Biosciences, Inc. Florham Park, USA	Oncology Hematology	Phase 2	VIEW
175.	Cellectis Paris, France	Oncology Immunology Rare Diseases	Phase 2	VIEW
176.	Cellestia Biotech AG Basel, Switzerland	Oncology Immunology	Phase 2	VIEW
177.	Celltrion Incheon, South Korea	Immunology Oncology Ophthalmology+2	Commercial	VIEW
178.	Celon Pharma Łomianki, Poland	Neuroscience Oncology Immunology+1	Phase 3	VIEW
179.	Celularity Inc Florham Park, New Jersey, USA	Oncology	Phase 1/2 and Phase 2	VIEW
180.	Center for Genetic Engineering and Biotechnology (CIGB) Havana, Cuba	Oncology Metabolic Infectious Disease+1	Commercial	VIEW
181.	Center for Neuromusculoskeletal Restorative Medicine Limited Shatin, Hong Kong	Neuroscience Rare Diseases	Preclinical	VIEW
182.	Center of Molecular Immunology (CIM) Havana, Cuba	Oncology Immunology	Commercial	VIEW
183.	Centessa Pharmaceuticals Altrincham, United Kingdom	Neuroscience	Phase 2	VIEW
184.	Centrexion Therapeutics Boston, Massachusetts, United States	Immunology	Phase 1-3	VIEW
185.	Cerevel Therapeutics Cambridge, Massachusetts, USA		Phase 1-3	VIEW
186.	Chan Zuckerberg Biohub Network San Francisco, USA	Infectious Disease Rare Diseases Immunology	Discovery	VIEW
187.	Changchun GeneScience Pharmaceutical Co., Ltd. Changchun, China	Metabolic Oncology Immunology+1	Clinical	VIEW
188.	Chongqing PegBio Biotechnology Co., Ltd. Chongqing, China	Gastroenterology Hematology Oncology	Phase 3	VIEW
189.	Choose Life Biotech SA Bellinzona, Switzerland	Immunology Infectious Disease Oncology	Preclinical	VIEW
190.	ChuanXin Biomedicine Suzhou, China	Infectious Disease Oncology	Phase 1	VIEW
191.	Circio Holding ASA Lysaker, Norway	Oncology Immunology Gene Therapy	Phase 1/2	VIEW
192.	City Therapeutics Cambridge, United States	Hematology Ophthalmology Rare Diseases	Phase 1 and preclinical	VIEW
193.	Clasp Therapeutics Rockville, Maryland, USA	Oncology	Phase 1	VIEW
194.	ClearB Therapeutics, Inc. Concord, Massachusetts, USA	Infectious Disease	Phase 1	VIEW
195.	Clinuvel Pharmaceuticals Melbourne, Australia	Rare Diseases Dermatology Neuroscience	Commercial	VIEW
196.	Coave Therapeutics Paris, France	Ophthalmology Neuroscience Rare Diseases	Preclinical	VIEW
197.	Codexis, Inc. Redwood City, California, USA	Rare Diseases Metabolic	Commercial	VIEW
198.	Coherus BioSciences, Inc. Redwood City, USA	Oncology	Commercial	VIEW
199.	Comanche Biopharma Corp. Concord, USA		Phase 1	VIEW
200.	Complement Therapeutics United Kingdom (University of Manchester spinout, with facilities in UK and Germany)	Ophthalmology	Phase I/II	VIEW
201.	Constructor Group Schaffhausen, Switzerland	Oncology Infectious Disease Neuroscience	Preclinical	VIEW
202.	Cook MyoSite, Inc. Pittsburgh, USA	Gastroenterology	Phase 3	VIEW
203.	Corbus Pharmaceuticals Holdings, Inc. Norwood, Massachusetts, USA	Oncology Metabolic	Phase 3	VIEW
204.	Corline Biomedical AB Uppsala, Sweden	Metabolic Cardiovascular Neuroscience	Phase 2	VIEW
205.	Cosmica Biosciences San Francisco, USA		Discovery	VIEW
206.	Coya Therapeutics, Inc. Houston, USA	Immunology	Phase 2	VIEW
207.	Createrna Science and Technology Wuhan, China	Cardiovascular Respiratory Immunology	Phase 2	VIEW
208.	Crescent Biopharma, Inc. Waltham, USA	Oncology	Phase 1/2	VIEW
209.	Cugene Inc. Waltham, USA	Oncology Immunology	Phase 1	VIEW
210.	Cullinan Therapeutics Cambridge, USA	Oncology Immunology	Phase 3	VIEW
211.	CuraTeQ Biologics Hyderabad, India	Oncology Immunology Metabolic	Commercial	VIEW
212.	CuraVac Rixensart, Belgium	Immunology	Phase 1B (completed) \| Phase 2 (in preparation)	VIEW
213.	Curadev Pharma Pvt Ltd Noida, India	Oncology Immunology Metabolic	Phase 1	VIEW
214.	Curasight Copenhagen, Denmark	Oncology	Phase 1-2 Clinical	VIEW
215.	Curative Biotechnology Inc Boca Raton, Florida, USA	Infectious Disease	Pre-Clinical\|IND-Enabling Studies	VIEW
216.	CureVac Tübingen, Germany	Oncology Infectious Disease Rare Diseases	Phase 2	VIEW
217.	Curis, Inc. Lexington, USA	Oncology	Phase 1/2	VIEW
218.	Curocell Inc. Daejeon, South Korea	Oncology Hematology	Commercial	VIEW
219.	Cytiva Marlborough, Massachusetts, USA	Oncology Immunology Rare Diseases+1	Commercial	VIEW
220.	CytoAgents Pittsburgh, USA	Oncology Immunology Infectious Disease+1	Phase 2	VIEW
221.	CytoDyn Inc Vancouver, Washington	Oncology Immunology	Phase 2 clinical	VIEW
222.	CytoHub Inc. San Diego, USA	Cardiovascular	Preclinical	VIEW
223.	CytoImmune Therapeutics Duarte, USA	Oncology Hematology Immunology	Phase 1	VIEW
224.	CytoSen Therapeutics Orlando (Winter Springs), Florida, USA	Oncology Cell Therapy Immunology	Phase 2	VIEW
225.	CytoTools AG Heidelberg, Germany	Dermatology Cardiovascular Oncology	Phase 3	VIEW
226.	CytoVac Hørsholm, Denmark	Oncology	Phase 2	VIEW
227.	Cytochroma Edinburgh, United Kingdom	Cardiovascular Rare Diseases	Discovery	VIEW
228.	Cytocom, Inc. Fort Collins, Colorado, USA	Oncology Infectious Disease Hematology+1	Phase 2/Phase 3	VIEW
229.	Cytokinetics, Incorporated South San Francisco, USA	Cardiovascular	Commercial	VIEW
230.	CytomX Therapeutics, Inc. South San Francisco, California, United States	Oncology	Phase 1 (clinical), Preclinical (discovery collaborations)	VIEW
231.	Cytomos Edinburgh, United Kingdom	Cell Therapy Gene Therapy Oncology	Commercial	VIEW
232.	Cytonics Corporation Jupiter, Florida, USA	Immunology	Phase 2	VIEW
233.	Cytonus Therapeutics Carlsbad, California, United States	Oncology Immunology Infectious Disease+1	Phase 1	VIEW
234.	Cytorex Biosciences Weston, Florida, USA	Oncology Metabolic Infectious Disease	Preclinical	VIEW
235.	Cytovation Bergen, Norway	Oncology Rare Diseases	Phase I/II - Phase II	VIEW
236.	Cytovia Therapeutics Aventura, Florida, USA	Oncology Immunology	Phase 1/2	VIEW
237.	Cyxone Malmö, Sweden	Immunology Neuroscience	Phase 2	VIEW
238.	D&D Pharmatech Seongnam-si, South Korea		Phase 2	VIEW
239.	DBV Technologies Châtillon, France	Immunology	Phase 3	VIEW
240.	Danaher Corporation Washington, D.C., USA	Oncology Infectious Disease	N/A	VIEW
241.	Day One Biopharmaceuticals Brisbane, United States	Oncology Rare Diseases	Commercial	VIEW
242.	Debiopharm Lausanne, Switzerland	Oncology Rare Diseases	Phase 1, Phase 2, Phase 3	VIEW
243.	Denali Therapeutics Inc. South San Francisco, USA		Commercial	VIEW
244.	Dendreon Pharmaceuticals Seal Beach, USA	Oncology	Commercial	VIEW
245.	DesiCorp Inc. Louisville, USA		Preclinical	VIEW
246.	DevaCell, Inc. San Diego, USA	Oncology Infectious Disease Gene Therapy	Preclinical	VIEW
247.	Development Center for Biotechnology (DCB) Taipei, Taiwan	Oncology Immunology Infectious Disease	Preclinical	VIEW
248.	Differential Bio Munich, Germany		Commercial	VIEW
249.	Dignify Therapeutics Research Triangle Park, NC, USA	Neuroscience Gastroenterology	Clinical	VIEW
250.	Disc Medicine, Inc. Watertown, Massachusetts, USA	Hematology Rare Diseases	Phase 3	VIEW
251.	Dolor Therapeutics, Inc. Chicago, USA	Immunology	Preclinical	VIEW
252.	Dompé Farmaceutici Milan, Italy	Ophthalmology Rare Diseases Metabolic+2	Commercial	VIEW
253.	Drishti Discoveries Ltd Cambridge, United Kingdom	Rare Diseases	Preclinical	VIEW
254.	Drugs for Neglected Diseases initiative (DNDi) Geneva, Switzerland	Infectious Disease	Commercial	VIEW
255.	Duality Biologics Shanghai, China	Oncology Immunology	Phase 3	VIEW
256.	Dyne Therapeutics, Inc. Waltham, Massachusetts, USA		Phase 1/2, Phase 3	VIEW
257.	E-Flask Seongnam, South Korea	Neuroscience Oncology	Phase 1	VIEW
258.	Edge Therapeutics, Inc. Princeton, New Jersey, USA	Oncology Infectious Disease	Phase 3	VIEW
259.	Edgewise Therapeutics Boulder, USA		Phase 2	VIEW
260.	EdiLabs OÜ Harku, Estonia	Neuroscience Immunology	Discovery	VIEW
261.	Eledon Pharmaceuticals Irvine, USA	Immunology	Phase 2	VIEW
262.	Elevar Therapeutics Fort Lee, USA	Oncology	Phase 3	VIEW
263.	Eleven Therapeutics Cambridge, United Kingdom	Infectious Disease	Discovery	VIEW
264.	Elixiron Immunotherapeutics Taipei, Taiwan	Oncology Immunology	Phase 2	VIEW
265.	Ellipses Pharma London, United Kingdom	Oncology	Phase 1/2	VIEW
266.	Emergent BioSolutions Gaithersburg, Maryland, USA	Infectious Disease	Commercial	VIEW
267.	Enanta Pharmaceuticals, Inc. Watertown, Massachusetts, USA	Immunology	Phase 1-2 clinical	VIEW
268.	Eneapharm Labège, France	Gastroenterology Rare Diseases	Clinical	VIEW
269.	Enlivex Therapeutics Ltd. Ness Ziona, Israel	Immunology Oncology Infectious Disease	Phase 2	VIEW
270.	Ensem Therapeutics Waltham, MA, USA	Oncology	Phase 1/2	VIEW
271.	Entact Bio Watertown, USA	Oncology Immunology Rare Diseases	Preclinical	VIEW
272.	Enveda Biosciences Boulder, USA	Immunology Metabolic Dermatology	Clinical	VIEW
273.	Enzo Biochem, Inc. Farmingdale, New York, USA	Oncology Infectious Disease	Discovery	VIEW
274.	Estetra SRL Liège, Belgium	Oncology	Commercial	VIEW
275.	EuBiologics Co., Ltd. Seoul, South Korea	Infectious Disease	Phase 3	VIEW
276.	Everest Medicines Shanghai, China	Immunology Oncology Cardiovascular+1	Commercial	VIEW
277.	Evopoint Biosciences Suzhou, China	Oncology Infectious Disease Immunology	Commercial (NDA Stage)	VIEW
278.	Evox Therapeutics Oxford, United Kingdom	Rare Diseases Oncology	Preclinical	VIEW
279.	Exelixis Alameda, USA	Oncology	Commercial	VIEW
280.	EyePoint Pharmaceuticals Watertown, Massachusetts, USA	Ophthalmology	Phase 3	VIEW
281.	FELIQS Corporation Fukuoka, Japan	Ophthalmology Rare Diseases	Phase 1	VIEW
282.	FNCT Biotech Seongnam-si, South Korea	Oncology Immunology	Preclinical	VIEW
283.	FORE Biotherapeutics Philadelphia, USA	Oncology	Phase 2	VIEW
284.	Faron Pharmaceuticals Turku, Finland	Oncology Hematology	Phase 2	VIEW
285.	Fate Therapeutics, Inc. San Diego, USA	Oncology	Phase 1	VIEW
286.	Feldan Therapeutics Québec City, Canada	Oncology Dermatology	Preclinical	VIEW
287.	Finnadvance Oulu, Finland	Ophthalmology Rare Diseases	Commercial	VIEW
288.	Fiocruz (Oswaldo Cruz Foundation) Rio de Janeiro, Brazil	Infectious Disease	Commercial	VIEW
289.	Fishfa Biogenics Rajkot, India	Immunology Infectious Disease Oncology+1	Commercial	VIEW
290.	Flare Therapeutics Cambridge, MA, USA	Oncology	Phase 1-1B	VIEW
291.	Floratek Pharma SA Belmont-sur-Lausanne, Switzerland	Oncology	Preclinical	VIEW
292.	FluGen, Inc. Madison, USA	Infectious Disease	Phase 2	VIEW
293.	Forma Therapeutics Inc Watertown, USA	Hematology Oncology Rare Diseases	Phase 3	VIEW
294.	Formation Bio New York, USA	Immunology Dermatology Neuroscience	Phase 3	VIEW
295.	Formycon AG Planegg-Martinsried, Germany	Ophthalmology Immunology	Commercial	VIEW
296.	Frontier Medicines South San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
297.	Fundação Butantan São Paulo, Brazil	Infectious Disease	Phase 2	VIEW
298.	Fusion Pharmaceuticals Inc. Hamilton, Ontario, Canada	Oncology	Phase 1\|Phase 2\|Phase 3	VIEW
299.	Future Health Biobank Nottingham, United Kingdom		-	VIEW
300.	GC Biopharma Corp. (formerly Green Cross Corporation) Yongin, Gyeonggi Province, South Korea	Hematology Neuroscience Respiratory+2	Multiple stages (Discovery through Commercial)	VIEW
301.	GENFIT Loos, France	Metabolic	Phase 2	VIEW
302.	GNT Pharma Yongin, South Korea	Neuroscience Respiratory	Phase 3	VIEW
303.	Galapagos NV Mechelen, Belgium	Immunology Oncology	Phase 2	VIEW
304.	Galenicap BV Brussels, Belgium	Oncology Neuroscience Infectious Disease	Phase 2	VIEW
305.	GenAns Biotech Beijing, China	Neuroscience Ophthalmology Oncology	Preclinical	VIEW
306.	GenLumina Leiden, Netherlands	Oncology	Preclinical	VIEW
307.	Gene Oasis Singapore, Singapore	Oncology Neuroscience Immunology+1	Clinical	VIEW
308.	GeneScience Pharmaceuticals Co., Ltd. (GenSci) Changchun, China	Metabolic Immunology Respiratory+1	Commercial	VIEW
309.	GeneTex, Inc. Irvine, USA	Oncology Immunology Neuroscience+1	-	VIEW
310.	Genentech South San Francisco, California, United States	Oncology Immunology Rare Diseases+3	Discovery through Commercial	VIEW
311.	Generare Paris, France	Oncology Immunology	Discovery	VIEW
312.	Genfarma Joint Stock Company Hanoi, Vietnam	Oncology Immunology Neuroscience+1	Commercial	VIEW
313.	Genmab Copenhagen, Denmark	Oncology Hematology Immunology	Commercial	VIEW
314.	Gensciences Nantong, China	Hematology	Phase 3	VIEW
315.	Gesynta Pharma AB Stockholm, Sweden		Phase 2	VIEW
316.	Google (Google DeepMind / Isomorphic Labs) London, United Kingdom	Oncology Immunology Cardiovascular	Preclinical	VIEW
317.	Gossamer Bio San Diego, United States		Phase 3 / NDA preparation	VIEW
318.	Granite Bio Basel, Switzerland	Immunology	Phase 1	VIEW
319.	Grit Biotechnology Shenzhen, China	Oncology Immunology	Phase 2	VIEW
320.	Guangzhou Cellprotek Pharmaceutical Guangzhou, China	Neuroscience Cardiovascular Immunology+1	Phase 3 (Planning)	VIEW
321.	HCW Biologics Inc. Miramar, Florida, USA	Oncology Immunology	Phase 2	VIEW
322.	HERVolution Therapeutics Copenhagen, Denmark	Oncology	Preclinical	VIEW
323.	HIPRA Amer, Spain		Commercial	VIEW
324.	HLB PEP Co., Ltd. Gwangju, South Korea	Oncology Rare Diseases Immunology	Preclinical	VIEW
325.	HUN-REN Veterinary Medical Research Institute (VMRI) Budapest, Hungary	Infectious Disease	Discovery	VIEW
326.	HUTCHMED Hong Kong	Oncology Immunology Dermatology	Discovery to Phase III	VIEW
327.	Halozyme Therapeutics San Diego, USA	Oncology Immunology Neuroscience+3	Commercial	VIEW
328.	Hansa Biopharma Lund, Sweden	Immunology Gene Therapy Oncology	Commercial	VIEW
329.	Harbour BioMed Shanghai, China	Oncology Immunology Ophthalmology	Phase 3	VIEW
330.	Healios K.K. Tokyo, Japan	Neuroscience Oncology Ophthalmology	Phase 3	VIEW
331.	Healis Therapeutics Cambridge, USA	Neuroscience	Phase 2/3	VIEW
332.	Heligenics Phoenix, Arizona, USA	Oncology Rare Diseases	Discovery	VIEW
333.	Hemerion Therapeutics Villeneuve d'Ascq, France	Oncology	Phase 1/2	VIEW
334.	HepaRegeniX GmbH Tübingen, Germany	Oncology Neuroscience	Phase 2	VIEW
335.	Heranova Lifesciences Burlington, MA, USA		Clinical	VIEW
336.	HighField Biopharmaceuticals Hangzhou, China	Oncology Metabolic	Phase 1	VIEW
337.	Holostem S.r.l. Modena, Italy	Ophthalmology Dermatology Rare Diseases	Commercial	VIEW
338.	Hone Bio Bristol, United Kingdom	Oncology Cardiovascular	Preclinical	VIEW
339.	Huahui Health Ltd. Beijing, China	Oncology	Commercial	VIEW
340.	Humatrix Medical Suzhou, China	Cardiovascular	Preclinical/Early Clinical	VIEW
341.	HyperMabs Inc. Montreal, Canada	Oncology Infectious Disease	Discovery	VIEW
342.	IDEAYA Biosciences South San Francisco, USA	Oncology	Phase 3	VIEW
343.	IMIDomics, Inc. San Rafael, USA	Immunology Dermatology	Discovery	VIEW
344.	IMTR Inc. Tokyo, Japan	Immunology Hematology Gastroenterology	Phase 1/2	VIEW
345.	IPS Biopharma AG Bern, Switzerland	Oncology Infectious Disease	Phase 2	VIEW
346.	Idorsia Allschwil, Switzerland	Neuroscience Cardiovascular Immunology+1	Commercial	VIEW
347.	Ignis Therapeutics Shanghai, China	Neuroscience	Phase 3	VIEW
348.	Immatics N.V. Tübingen, Germany	Oncology	Phase 2	VIEW
349.	Immorna Biotherapeutics Morrisville, USA	Oncology Infectious Disease Dermatology+1	Phase 2	VIEW
350.	Immune System Key Ltd. (ISK) Jerusalem, Israel	Oncology	Phase 2	VIEW
351.	Immuneel Therapeutics Bengaluru, India	Oncology Hematology Immunology	Commercial	VIEW
352.	Immunethep Cantanhede, Portugal	Infectious Disease Immunology	Preclinical	VIEW
353.	Immunis, Inc. Irvine, California, USA	Immunology	Phase 1/2	VIEW
354.	ImmunityBio, Inc. Culver City, California, USA	Oncology Infectious Disease	Commercial	VIEW
355.	Immunocore Abingdon, United Kingdom	Oncology Infectious Disease Immunology	Commercial	VIEW
356.	Immunome, Inc. Bothell, Washington, USA	Oncology	Phase 3	VIEW
357.	Immunomic Therapeutics, Inc. Rockville, Maryland, United States	Oncology Infectious Disease	Phase 1 - Phase 2	VIEW
358.	Immunophotonics Saint Louis, Missouri, USA	Oncology Immunology	Phase 2/3	VIEW
359.	Immunovant, Inc. Durham, North Carolina, USA	Immunology Neuroscience Metabolic+1	Phase 3	VIEW
360.	Impact Therapeutics, Inc. Shanghai, China	Oncology	Commercial	VIEW
361.	Incepta Vaccine Ltd. Dhaka, Bangladesh	Infectious Disease	Commercial	VIEW
362.	Indian Immunologicals Limited Hyderabad, India	Infectious Disease Immunology	Commercial	VIEW
363.	Industrial Technology Research Institute (ITRI) Hsinchu County, Taiwan		Discovery	VIEW
364.	Infinitopes Oxford, United Kingdom	Oncology	Phase 1/IIa	VIEW
365.	Inhibrx Biosciences, Inc. La Jolla, California, USA	Oncology	Phase 2/3	VIEW
366.	Initial Therapeutics South San Francisco, USA	Oncology Rare Diseases	Discovery	VIEW
367.	InnoMedica Bern, Switzerland	Oncology	Phase 2	VIEW
368.	Innovacell Tokyo, Japan	Gastroenterology	Phase 3	VIEW
369.	Innovative Cell Technologies, Inc. San Diego, United States		Commercial	VIEW
370.	Insilico Medicine Boston, USA	Oncology Immunology Neuroscience	Phase 2	VIEW
371.	InsilicoX Co., Ltd. Seoul, South Korea		Discovery	VIEW
372.	Insmed Incorporated Bridgewater, New Jersey, USA	Immunology Rare Diseases	Commercial	VIEW
373.	Institute for Bioengineering of Catalonia (IBEC) Barcelona, Spain	Oncology Neuroscience Rare Diseases+2	Preclinical	VIEW
374.	Institute of Immunology (Imunološki zavod) Zagreb, Croatia	Infectious Disease Immunology	Discovery	VIEW
375.	Intellia Therapeutics Cambridge, USA	Rare Diseases Cardiovascular Neuroscience+2	Phase 3	VIEW
376.	Intelligene Taipei, Taiwan	Infectious Disease	Phase 1	VIEW
377.	International Centre of Insect Physiology and Ecology (ICIPE) Nairobi, Kenya	Infectious Disease	Discovery\|Preclinical\|Phase 2	VIEW
378.	International Livestock Research Institute (ILRI) Nairobi, Kenya	Infectious Disease	Commercial	VIEW
379.	Interventional AnalgesiX Inc. Durham, North Carolina, United States		Preclinical	VIEW
380.	Intrommune Therapeutics New York, USA	Immunology	Phase 1	VIEW
381.	Inventiva Pharma Daix, France	Oncology	Phase 3	VIEW
382.	Ionis Pharmaceuticals, Inc. Carlsbad, California, United States	Neuroscience Cardiovascular Immunology+1	Phase 1 through Commercial	VIEW
383.	Ionis Pharmaceuticals, Inc. Carlsbad, USA	Neuroscience Rare Diseases	Commercial	VIEW
384.	J-Pharma Co., Ltd. Tokyo, Japan	Oncology Neuroscience Immunology	Phase 3	VIEW
385.	JCR Pharmaceuticals Co., Ltd. Ashiya, Japan	Rare Diseases Neuroscience	Phase 3	VIEW
386.	Janux Therapeutics San Diego, California, USA	Oncology Immunology	Phase 1	VIEW
387.	Japan Institute for Health Security Shinjuku-ku, Tokyo, Japan	Infectious Disease Vaccines	Discovery	VIEW
388.	Jiayue Pharmaceutical Guangzhou, China	Oncology Immunology Infectious Disease	Phase 3	VIEW
389.	Josep Carreras Leukaemia Research Institute (IJC) Badalona, Spain		Discovery	VIEW
390.	Jubilant Therapeutics Bedminster, NJ, United States	Oncology Immunology	Phase I/II Clinical	VIEW
391.	Junshi Biosciences Shanghai, China	Oncology Immunology Metabolic+1	Commercial	VIEW
392.	KM Biologics Co., Ltd. Kumamoto, Japan	Infectious Disease Hematology Immunology	Commercial	VIEW
393.	Kailera Therapeutics Waltham, MA, USA	Metabolic	Phase 3	VIEW
394.	Kali Therapeutics, Inc. San Mateo, California, USA	Oncology	Phase 1	VIEW
395.	KaliVir Immunotherapeutics Pittsburgh, Pennsylvania, USA	Oncology Immunology	Phase 1/1b Clinical	VIEW
396.	Kardigan South San Francisco, USA		Phase 2/3	VIEW
397.	Karyon Bio Bengaluru, India (with US presence in Mountain View, California)		Discovery	VIEW
398.	Karyopharm Therapeutics Newton, Massachusetts, USA	Oncology Hematology	Commercial	VIEW
399.	Kashiv BioSciences Piscataway, New Jersey, USA	Oncology Immunology	Phase 3	VIEW
400.	Kedrion Biopharma Barga, Italy	Immunology Hematology Rare Diseases	Commercial	VIEW
401.	Kenai Therapeutics San Diego, USA	Neuroscience	Phase 1	VIEW
402.	Keros Therapeutics Lexington, Massachusetts, United States	Hematology Respiratory Cardiovascular	Phase 1-3	VIEW
403.	Keymed Biosciences Chengdu, China	Immunology Oncology	Commercial	VIEW
404.	Khartis Therapeutics, Inc. San Diego, USA	Immunology	Discovery	VIEW
405.	Kiniksa Pharmaceuticals London, United Kingdom	Cardiovascular Immunology Rare Diseases	Commercial	VIEW
406.	Kite Pharma Santa Monica, USA	Oncology	Commercial	VIEW
407.	Kodiak Sciences Inc. Palo Alto, USA	Ophthalmology	Phase 3	VIEW
408.	Kolon Group Gwacheon, South Korea	Neuroscience Oncology Dermatology	Phase 3	VIEW
409.	Korea Research Institute of Bioscience and Biotechnology Daejeon, South Korea	Oncology Infectious Disease	Discovery	VIEW
410.	Korro Bio, Inc. Cambridge, USA	Rare Diseases Neuroscience	Phase 1/2	VIEW
411.	KromaTiD, Inc. Longmont, USA	Oncology Rare Diseases Gene Therapy+1	Discovery	VIEW
412.	Kura Oncology Inc San Diego, California, USA	Oncology	Phase 1\|Phase 2\|Phase 3\|Approved	VIEW
413.	Kymera Therapeutics, Inc. Watertown, Massachusetts, USA	Immunology Oncology	Phase 2	VIEW
414.	LFB USA Framingham, USA	Immunology	Commercial	VIEW
415.	Lamark Biotech Ahmedabad, India	Oncology	Preclinical	VIEW
416.	Laurent Pharmaceuticals Montreal, Quebec, Canada		Phase 2/3	VIEW
417.	Legend Biotech Somerset, USA	Oncology Infectious Disease	Commercial	VIEW
418.	Legend Biotech Somerset, New Jersey, USA	Oncology Hematology Infectious Disease	Commercial	VIEW
419.	Lepu Biopharma Co., Ltd. Shanghai, China	Oncology	Commercial	VIEW
420.	LiBo Pharma Corp. New Taipei City, Taiwan	Oncology Hematology Immunology	Phase 2/Phase 3	VIEW
421.	Libio Technology Suzhou, China	Cardiovascular Metabolic	Phase 1	VIEW
422.	Lion TCR Singapore, Singapore	Oncology Infectious Disease	Phase 2	VIEW
423.	MAB Discovery GmbH Polling, Germany	Oncology Immunology	Preclinical	VIEW
424.	MEPSGEN Seoul, South Korea	Neuroscience Oncology Rare Diseases	Preclinical	VIEW
425.	Mahzi Therapeutics South San Francisco, USA	Rare Diseases	Phase 1/2	VIEW
426.	MannKind Corporation Westlake Village, California, USA	Metabolic	Commercial	VIEW
427.	Mariana Oncology (via Carroll Bio Advisory) Watertown, Massachusetts	Oncology	Phase 1	VIEW
428.	Marinomed Biotech AG Korneuburg, Austria	Immunology Ophthalmology	Phase 3	VIEW
429.	MediLink Therapeutics Suzhou, China	Oncology	Phase 2	VIEW
430.	MedinCell Montpellier, France		Commercial\|Phase 3\|Preclinical	VIEW
431.	Medytox Inc. Seoul, South Korea	Neuroscience Dermatology	Phase 3	VIEW
432.	Mersana Therapeutics Cambridge, USA	Oncology Rare Diseases	Phase 1	VIEW
433.	Merus N.V. Utrecht, Netherlands	Oncology	Commercial (BLA Stage)	VIEW
434.	Mesa Green Pharma Frederick, USA	Neuroscience	Preclinical	VIEW
435.	Metagenomi Emeryville, USA	Hematology Cardiovascular Rare Diseases+1	Preclinical	VIEW
436.	Metagenomi Therapeutics, Inc. Emeryville, United States	Hematology Rare Diseases	Preclinical	VIEW
437.	MetrioPharm AG Zurich, Switzerland	Infectious Disease Rare Diseases Immunology	Phase 2	VIEW
438.	Micro CRISPR Vapi, India	Oncology Hematology Metabolic+1	Preclinical	VIEW
439.	Miltenyi Biotec Bergisch Gladbach, Germany	Oncology Immunology Hematology	Commercial	VIEW
440.	Minovia Therapeutics Tirat Carmel, Israel	Rare Diseases Hematology	Phase 2	VIEW
441.	Mirum Pharmaceuticals Foster City, USA	Rare Diseases	Commercial	VIEW
442.	Mobius Care Cleveland, USA		Discovery	VIEW
443.	Mogam Institute for Biomedical Research Seoul, South Korea	Rare Diseases Infectious Disease Oncology+1	Discovery\|Preclinical	VIEW
444.	Monimoi Therapeutics Boston, USA	Oncology	Discovery	VIEW
445.	Monte Rosa Therapeutics Boston, USA	Oncology Immunology	Phase 1/2	VIEW
446.	Mucpharm Kogarah, Sydney, New South Wales 2217, Australia	Oncology Rare Diseases	Phase 2	VIEW
447.	MultiOmic Health London, United Kingdom	Metabolic	Discovery	VIEW
448.	Muna Therapeutics Frederiksberg, Denmark		Phase 1	VIEW
449.	Myrio Therapeutics Melbourne, Australia	Oncology	Discovery	VIEW
450.	N4 Pharma Chellaston, Derbyshire, United Kingdom	Oncology	Preclinical	VIEW
451.	NBE Therapeutics Basel, Switzerland	Oncology	Phase 1/2	VIEW
452.	NEUVOGEN, Inc. San Diego, USA	Oncology	Clinical	VIEW
453.	NKure Therapeutics Bengaluru, India	Oncology Infectious Disease	Preclinical	VIEW
454.	NMD Pharma A/S Aarhus, Denmark		Phase 2	VIEW
455.	Naiji Pharmaceutical Technology (Hangzhou) Co., Ltd. Hangzhou, China	Gene Therapy	Discovery	VIEW
456.	Nalu Bio San Francisco, USA		Preclinical	VIEW
457.	Nanjing Vazyme Biotech Co., Ltd. Nanjing, China	Infectious Disease Oncology Cardiovascular	Commercial	VIEW
458.	Nanocan Therapeutics Corporation Princeton, New Jersey (also noted as National Harbor, MD)	Oncology	Phase I/II	VIEW
459.	Nanogen Pharmaceutical Biotechnology JSC Ho Chi Minh City, Vietnam	Oncology Infectious Disease	Commercial	VIEW
460.	Nanophoria Milan, Italy	Cardiovascular Rare Diseases	Preclinical	VIEW
461.	Nanoscope Therapeutics Dallas, USA	Ophthalmology	Commercial	VIEW
462.	Navigator Medicines, Inc. Scotch Plains, New Jersey, USA	Immunology	Phase 2a (NAV-240), Phase 1 (NAV-242)	VIEW
463.	Nektar Therapeutics San Francisco, USA	Immunology	Phase 2	VIEW
464.	NervGen Pharma Corp. Vancouver, Canada	Neuroscience	Phase 3	VIEW
465.	Nerviano Medical Sciences Nerviano, Italy	Oncology Hematology	Phase 2	VIEW
466.	NeuCyte, Inc. San Carlos, United States	Neuroscience	Preclinical	VIEW
467.	Neuhyll Therapeutics, Inc. Newbury Park, USA		Phase 1	VIEW
468.	NeuroSense Therapeutics Herzliya, Israel		Phase 3	VIEW
469.	Neurocrine Biosciences San Diego, USA	Neuroscience Metabolic Rare Diseases	Commercial	VIEW
470.	Neurogene Inc. New York, NY	Neuroscience Rare Diseases	Phase 2	VIEW
471.	Neurophth Therapeutics Wuhan, China	Ophthalmology Rare Diseases	Phase 3	VIEW
472.	NextCure, Inc. Beltsville, Maryland, USA	Oncology Immunology	Phase 2	VIEW
473.	Nippi, Inc. Adachi-ku, Tokyo, Japan	Dermatology	Commercial	VIEW
474.	NorthStar Medical Radioisotopes, LLC Beloit, Wisconsin, USA	Oncology Cardiovascular	Commercial	VIEW
475.	Notogen Inc. Toronto, Canada		Preclinical	VIEW
476.	Nouveau Biosciences, Inc. Scarsdale, New York, USA	Oncology	Preclinical	VIEW
477.	NovaBridge Biosciences Rockville, Maryland, USA	Oncology Ophthalmology	Phase 2	VIEW
478.	Noveome Biotherapeutics Pittsburgh, Pennsylvania, USA	Ophthalmology Neuroscience Dermatology	Phase 1-2	VIEW
479.	Novonesis Lyngby, Denmark		Commercial	VIEW
480.	Numab Therapeutics AG Horgen, Switzerland	Oncology Immunology Dermatology	Clinical	VIEW
481.	NurExone Biologic Inc. Toronto, Canada / Haifa, Israel	Neuroscience	Preclinical	VIEW
482.	Nurix Therapeutics, Inc. San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
483.	Nuvalent, Inc. Cambridge, USA	Oncology	Phase 2	VIEW
484.	Nuvation Bio New York, United States	Oncology	Commercial	VIEW
485.	OSIVAX Lyon, France		Phase 2	VIEW
486.	OSR Health, Inc. Bellevue, USA	Oncology	Phase 2	VIEW
487.	Oban BioPharma Stamford, USA	Neuroscience	Preclinical	VIEW
488.	Obsidian Therapeutics Cambridge, Massachusetts, USA	Oncology	Phase 2	VIEW
489.	Ocugen, Inc. Malvern, Pennsylvania, USA	Ophthalmology Infectious Disease	Phase 3	VIEW
490.	Ocular Therapeutix, Inc. Bedford, Massachusetts, USA	Ophthalmology	Commercial	VIEW
491.	Okklo Life Sciences Nijmegen, Netherlands	Hematology Immunology Oncology	Phase 1	VIEW
492.	OliX Pharmaceuticals Seongnam, South Korea	Ophthalmology Dermatology Neuroscience	Phase 2	VIEW
493.	Omeros Corporation Seattle, United States	Oncology Immunology	Commercial	VIEW
494.	OmniAb, Inc. Emeryville, California, USA	Oncology Immunology Neuroscience+1	Discovery	VIEW
495.	On/Off Therapeutics Paris, France	Oncology Immunology Rare Diseases	Preclinical	VIEW
496.	OnKure Therapeutics, Inc. Boulder, Colorado, USA	Oncology	Phase 1	VIEW
497.	OncoNex-Remunity Therapeutics Houston, USA / Paris, France	Oncology	Phase 1/2	VIEW
498.	OncoWise Bio Sydney, Australia	Oncology	Discovery	VIEW
499.	Oncogenexe Biotech Pty Ltd Fourways, South Africa	Oncology Infectious Disease Immunology+1	Phase 2	VIEW
500.	Onconic Therapeutics Gangnam-gu, Seoul, South Korea	Oncology	Approved\|Phase 2\|Phase 3	VIEW